BR112021018409A2 - Anticorpos e métodos para tratamento de infecção por influenza a - Google Patents

Anticorpos e métodos para tratamento de infecção por influenza a

Info

Publication number
BR112021018409A2
BR112021018409A2 BR112021018409A BR112021018409A BR112021018409A2 BR 112021018409 A2 BR112021018409 A2 BR 112021018409A2 BR 112021018409 A BR112021018409 A BR 112021018409A BR 112021018409 A BR112021018409 A BR 112021018409A BR 112021018409 A2 BR112021018409 A2 BR 112021018409A2
Authority
BR
Brazil
Prior art keywords
antibodies
methods
influenza infection
treating influenza
infection
Prior art date
Application number
BR112021018409A
Other languages
English (en)
Portuguese (pt)
Inventor
Davide Corti
Fabio Benigni
Original Assignee
Humabs Biomed Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Humabs Biomed Sa filed Critical Humabs Biomed Sa
Publication of BR112021018409A2 publication Critical patent/BR112021018409A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/108—Orthomyxoviridae (F), e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112021018409A 2019-04-30 2020-04-30 Anticorpos e métodos para tratamento de infecção por influenza a BR112021018409A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/EP2019/061134 WO2020221450A1 (en) 2019-04-30 2019-04-30 Antibodies and methods for treatment of influenza a infection
PCT/EP2020/062160 WO2020221908A1 (en) 2019-04-30 2020-04-30 Antibodies and methods for treatment of influenza a infection

Publications (1)

Publication Number Publication Date
BR112021018409A2 true BR112021018409A2 (pt) 2021-11-23

Family

ID=66429359

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021018409A BR112021018409A2 (pt) 2019-04-30 2020-04-30 Anticorpos e métodos para tratamento de infecção por influenza a

Country Status (17)

Country Link
US (1) US20220226470A1 (https=)
EP (1) EP3962530A1 (https=)
JP (1) JP7719725B2 (https=)
KR (1) KR20220003000A (https=)
CN (2) CN114269381A (https=)
AU (1) AU2020265407B2 (https=)
BR (1) BR112021018409A2 (https=)
CA (1) CA3132536A1 (https=)
CL (1) CL2021002807A1 (https=)
CO (1) CO2021012583A2 (https=)
EA (1) EA202192923A1 (https=)
IL (1) IL287423A (https=)
MX (1) MX2021012984A (https=)
PH (1) PH12021552176A1 (https=)
SG (1) SG11202109683TA (https=)
TW (1) TW202106707A (https=)
WO (2) WO2020221450A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102820941B1 (ko) 2018-01-26 2025-06-16 리제너론 파마슈티칼스 인코포레이티드 인플루엔자 헤마글루티닌에 대한 인간 항체
IL290752B2 (en) * 2019-08-29 2026-02-01 Vir Biotechnology Inc Preparations and methods for treating influenza a infection
US20230340083A1 (en) * 2020-12-08 2023-10-26 Vir Biotechnology, Inc. Antibodies and methods for treatment of influenza a infection
CN112812095A (zh) * 2021-01-29 2021-05-18 成都安满生物医药科技有限公司 一种巴洛沙韦酯中间体的合成方法
WO2023201306A1 (en) 2022-04-14 2023-10-19 Invisishield Technologies Ltd. Compositions for preventing or treating influenza infections
CN115777944B (zh) * 2023-02-10 2023-05-12 北京衡美金叶营养健康科技有限公司 增强身体防御力的组合物及其制备方法和应用
IL325937A (en) * 2023-07-24 2026-03-01 Univ Miami AAV-delivered antibodies and methods of using them

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004076677A2 (en) 2003-02-26 2004-09-10 Institute For Research In Biomedicine Monoclonal antibody production by ebv transformation of b cells
US8802820B2 (en) * 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
BRPI0914092B1 (pt) 2008-10-22 2021-08-31 Institute For Research In Biomedicine Método de produção de um anticorpo a partir de células plasmáticas, método de produção de um anticorpo monoclonal a partir de células plasmáticas e método de produção de um anticorpo ou de um fragmento de anticorpo
US8326547B2 (en) 2009-10-07 2012-12-04 Nanjingjinsirui Science & Technology Biology Corp. Method of sequence optimization for improved recombinant protein expression using a particle swarm optimization algorithm
EP2638072A4 (en) 2010-11-12 2014-05-07 Univ Rockefeller FUSION PROTEINS FOR HIV THERAPY
JP6396313B2 (ja) 2012-12-07 2018-09-26 ファイザー・インク 操作された単量体抗体断片
EP3733244A1 (en) 2013-10-02 2020-11-04 Medlmmune, LLC Neutralizing anti-influenza a antibodies and uses thereof
WO2017123685A1 (en) 2016-01-13 2017-07-20 Medimmune, Llc Method of treating influenza a

Also Published As

Publication number Publication date
EP3962530A1 (en) 2022-03-09
WO2020221450A1 (en) 2020-11-05
PH12021552176A1 (en) 2022-09-12
CO2021012583A2 (es) 2021-10-20
CA3132536A1 (en) 2020-11-05
CL2021002807A1 (es) 2022-08-19
JP7719725B2 (ja) 2025-08-06
AU2020265407A1 (en) 2021-10-07
CN114269381A (zh) 2022-04-01
EA202192923A1 (ru) 2022-02-16
US20220226470A1 (en) 2022-07-21
AU2020265407B2 (en) 2026-01-08
TW202106707A (zh) 2021-02-16
KR20220003000A (ko) 2022-01-07
SG11202109683TA (en) 2021-11-29
MX2021012984A (es) 2021-12-10
CN119192357A (zh) 2024-12-27
IL287423A (en) 2021-12-01
WO2020221908A1 (en) 2020-11-05
JP2022531556A (ja) 2022-07-07

Similar Documents

Publication Publication Date Title
BR112021018409A2 (pt) Anticorpos e métodos para tratamento de infecção por influenza a
BR112022000503A2 (pt) Compostos úteis para tratar infecções por vírus influenza
MX2021008146A (es) Polinucleotidos de arn encapsulado y metodos de uso.
MX2022016066A (es) Nuevo inhibidor de proteina-cinasa-cinasa activada por mitogeno (mek) para el tratamiento de infecciones virales y bacterianas.
BR112019017403A2 (pt) composições e métodos para o tratamento de câncer
BR112017021021A2 (pt) inibidores de indolamina-2,3-dioxigenase para o tratamento de câncer
BR112016004073A2 (pt) conjugados anti-dll3 criados por engenharia e métodos de uso
BR112016026556A8 (pt) inibidores de mek, de p38 e/ou de nfkb, seus usos, composição, sistema de teste in vitro, seu uso, e método para detecção de moléculas eficazes na profilaxia e/ou tratamento de uma co-infecção
BR112018073238A2 (pt) vírus oncolíticos compreendendo esrage e métodos de tratamento de câncer
BR112021022951A2 (pt) Composições e métodos para o tratamento de doenças mediadas por atpase
BR112021017551A2 (pt) Uso de vírus oncolíticos para o tratamento de câncer
BR112017024481A2 (pt) inibidores de ebna1 e métodos de uso dos mesmos
BR112017002809A2 (pt) métodos para tratar câncer cervical
BR112016011079A2 (pt) ?inibidores de ebna1 e seu método de uso?
BR112021022806A2 (pt) Método para tratar a infecção crônica por hbv, sirna, usos de um sirna, e de um sirna e peg-ifna e de um sirna, peg-ifna e um nrti, método, composição para uso ou uso e kit
BR112022021562A2 (pt) Partículas interferentes terapêuticas para o coronavírus
MX2022009476A (es) Anticuerpos anti-tmprss2 y fragmentos de union a antigeno.
BR112017010298A2 (pt) anticorpos que neutralizam de modo potente vírus da raiva e outros lissavírus e usos dos mesmos
BR112022024149A2 (pt) Anticorpos antiglicoproteína spike de anti-sars-cov-2 e fragmentos de ligação a antígeno
BR112021019120A2 (pt) Células t específicas para antígenos de múltiplos vírus respiratórios e métodos de produção e uso das mesmas terapeuticamente
MX389454B (es) Sistemas y métodos para reducir las corrientes parásitas no deseadas.
BR112019023948A2 (pt) tratamento de cistos epiteliais por injeção intracística de partículas antineoplásicas
BR112022002025A2 (pt) Composições e métodos para tratar águas residuais
BR112021020605A2 (pt) Inibidor de mek para o tratamento de infecções virais e bacterianas
BR112023016241A2 (pt) Anticorpos que se ligam ao metapneumovírus, proteínas antigênicas de metapneumovírus e usos dos mesmos